Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker

Esaxerenone is a novel selective mineralocorticoid receptor (MR) blocker that was recently approved in Japan to treat hypertension. In phase II and III studies, esaxerenone plus a renin–angiotensin system inhibitor markedly reduced the urinary albumin-to-creatinine ratio (UACR) in hypertensive patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Arai, Kiyoshi, Morikawa, Yuka, Ubukata, Naoko, Sugimoto, Kotaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685977/
https://www.ncbi.nlm.nih.gov/pubmed/32616846
http://dx.doi.org/10.1038/s41440-020-0495-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685977/
https://www.ncbi.nlm.nih.gov/pubmed/32616846
http://dx.doi.org/10.1038/s41440-020-0495-0

Ejemplares similares